

Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Nolan, BJ;Zwickl, S;Locke, P;Cheung, AS

Title:

Testosterone and Quality of Life in Transgender and Gender-Diverse Adults Seeking Masculinization: A Secondary Analysis of a Randomized Clinical Trial

Date:

2024-10

Citation:

Nolan, B. J., Zwickl, S., Locke, P. & Cheung, A. S. (2024). Testosterone and Quality of Life in Transgender and Gender-Diverse Adults Seeking Masculinization: A Secondary Analysis of a Randomized Clinical Trial. *JAMA Network Open*, 7 (10), pp.1-4. <https://doi.org/10.1001/jamanetworkopen.2024.43466>.

Persistent Link:

<https://hdl.handle.net/11343/356503>

License:

[CC BY](#)



Research Letter | Diabetes and Endocrinology

Testosterone and Quality of Life in Transgender and Gender-Diverse Adults Seeking Masculinization

A Secondary Analysis of a Randomized Clinical Trial

Brendan J. Nolan, PhD; Sav Zwickl, PhD; Peter Locke; Ada S. Cheung, PhD

Introduction

Testosterone treatment is a necessary component of gender affirmation for some transgender and gender-diverse adults seeking masculinization. We have previously demonstrated¹ that early access to testosterone therapy, compared with commencement following a standard care waiting list of 3 months, reduces gender dysphoria, depression, and suicidality in transgender and gender-diverse adults. Observational studies^{2,3} have demonstrated associations between testosterone commencement and improvements in quality of life; however, no randomized clinical trial has been performed that we know of. We aimed to examine the outcomes of early access to testosterone therapy, compared with no treatment, on quality of life and hypothesized that early access to testosterone therapy would improve quality of life.

Methods

In this prespecified secondary analysis of a randomized clinical trial, we recruited transgender and gender-diverse adults seeking initiation of testosterone as previously described.¹ Participants provided written informed consent, and the trial was approved by the human research ethics committee at Austin Health and registered with the Australian New Zealand clinical trials registry ([ANZCTR 12621000716864](#)). This study followed the Consolidated Standards of Reporting Trials ([CONSORT](#)) reporting guideline. The trial protocol is available in [Supplement 1](#), and the CONSORT flow diagram is shown as eFigure in [Supplement 2](#).

Participants were randomized to immediate testosterone commencement (intervention group) within 1 week of the first study visit or no treatment (commencement of testosterone following a standard care waiting list of 3 months). Participants completed the EuroQol (EQ-5D-5L) quality of life questionnaire at baseline and 3 months.⁴ The descriptive system comprises 5 dimensions: mobility, self-care, usual activities, pain and/or discomfort, and anxiety and/or depression, where each dimension has 5 potential responses (from no to extreme problems). Utility scores were generated using the UK general population-based value set, where values range from -0.285 to 1, and values less than 0 indicate a state worse than death.⁵ The EQ-VAS is a visual analogue scale that enables participants to assign a value to their overall health rating using a visual analogue scale from 0 ("The worst health you can imagine") to 100 ("The best health you can imagine").

Analysis of covariance was used to estimate the mean difference and corresponding 95% CI between the intervention group and the standard care group, adjusted for the corresponding measure at baseline.⁶ A 2-tailed significance level of $P < .05$ was used. Statistical analyses were performed using STATA version 17.0 (StataCorp LLC) from July to September 2023.

Results

Of 64 transgender and gender-diverse adults enrolled in the study, 62 completed the 3-month follow-up (31 in the intervention and standard care arms). Baseline characteristics have been

+ Supplemental content

Author affiliations and article information are listed at the end of this article.

Open Access. This is an open access article distributed under the terms of the CC-BY License.

previously published and are reproduced in **Table 1**.¹ Compared with controls, in individuals receiving testosterone, there was a clinically significant improvement in EQ-VAS over 3 months of follow-up (mean difference, 11.6 points; 95% CI, 4.9 to 18.3 points; *P* = .02) (**Table 2**). The between-group change in EQ-5D-5L utility index was not significant (mean difference, 0.07 points; 95% CI, -0.07 to 0.21 points; *P* = .06). In a sensitivity analysis, there were no between-group differences in the 5 dimensions of EQ-5D-5L (Table 2).

Table 1. Baseline Characteristics

Characteristic	Participants, No. (%)	
	Intervention (n = 31)	Standard care (n = 31)
Age, median (IQR), y	23 (20-28)	22 (20-27)
Gender identity		
Binary	17 (55)	15 (48)
Nonbinary	14 (45)	16 (52)
Comorbidities		
Depression	23 (74)	18 (58)
Anxiety	20 (65)	20 (65)
ASD	8 (26)	4 (13)
ADHD	8 (26)	6 (19)
Residence		
Metropolitan	23 (74)	25 (81)
Rural/remote	8 (26)	6 (19)
Employment status		
Employed/student	23 (74)	26 (84)
Unemployed	8 (26)	5 (16)
Total testosterone, mean (SD), ng/dL	37.5 (20.2)	25.9 (14.4)

Abbreviations: ADHD, attention deficit hyperactivity disorder; ASD, autism spectrum disorder.

SI conversion factor: To convert testosterone to nmol/L, multiply by 0.0347.

Table 2. Quality of Life Measures in Individuals Receiving Immediate Commencement Testosterone Compared With Those Receiving Standard Care

Parameter	Measure, Mean (SD)		Mean difference (95% CI) ^a	<i>P</i> value
	Intervention (n = 31)	Standard care (n = 31)		
EQ-5D-5L utility index				
0 mo	0.70 (0.21)	0.74 (0.17)	-0.07 (-0.07 to 0.21)	.06
3 mo	0.79 (0.16)	0.74 (0.19)		
EQ-5D-5L VAS				
0 mo	56.6 (19.8)	57.0 (21.7)	11.6 (4.9 to 18.3)	.02
3 mo	69.1 (20.6)	57.6 (21.9)		
EQ-5D-5L dimensions				
Mobility				
0 mo	1.35 (0.75)	1.19 (0.48)	0.13 (-0.08 to 0.34)	.21
3 mo	1.23 (0.62)	1.26 (0.51)		
Self-care				
0 mo	1.77 (0.92)	1.68 (0.79)	0.34 (-0.01 to 0.68)	.06
3 mo	1.45 (0.62)	1.74 (0.93)		
Usual activities				
0 mo	2.13 (1.02)	2.26 (0.89)	0.13 (-0.35 to 0.60)	.54
3 mo	1.94 (1.12)	2.13 (0.96)		
Pain/discomfort				
0 mo	1.87 (0.96)	1.65 (0.88)	0.35 (-0.06 to 0.76)	.09
3 mo	1.61 (0.76)	1.87 (0.99)		
Anxiety/depression				
0 mo	3.00 (0.89)	2.81 (0.95)	0.40 (-0.06 to 0.86)	.08
3 mo	2.35 (1.08)	2.65 (1.02)		

Abbreviations: EQ-5D-5L, EuroQol; VAS, visual analogue scale.

^a The mean difference and 95% CI refer to the between-group difference over 3 months adjusted for the corresponding measure at baseline.

Discussion

In this secondary analysis of a randomized clinical trial of transgender and gender-diverse adults seeking initiation of testosterone, there was a clinically meaningful improvement in self-rated health via the EQ-VAS, but the change in EQ-5D-5L utility index was not significant. Study limitations include the short follow-up period, open-label study design, and that EQ-5D-5L has not been validated in the transgender and gender-diverse population. Some of the EQ-5D-5L dimensions, such as mobility or pain, would not necessarily be expected to improve with testosterone. In contrast with our previous findings,¹ we also did not find a difference in the anxiety and/or depression dimension of EQ-5D-5L, which could indicate a lack of sensitivity of the outcome measure or insufficient sample size.

Our findings support the use of testosterone to improve self-reported health. Further research is needed to determine the optimal quality of life measure in the transgender and gender-diverse population.

ARTICLE INFORMATION

Accepted for Publication: September 15, 2024.

Published: October 25, 2024. doi:10.1001/jamanetworkopen.2024.43466

Open Access: This is an open access article distributed under the terms of the [CC-BY License](#). © 2024 Nolan BJ et al. *JAMA Network Open*.

Corresponding Author: Brendan J. Nolan, MBBS, PhD, Department of Medicine (Austin Health), The University of Melbourne, Studley Road, Heidelberg, VIC 3084, Australia (nolan.b@unimelb.edu.au).

Author Affiliations: Trans Health Research Group, Department of Medicine (Austin Health), University of Melbourne, Heidelberg, Victoria, Australia (Nolan, Zwickl, Cheung); Equinox Gender Diverse Clinic, Thorne Harbour Health, Abbotsford, Victoria, Australia (Nolan, Locke); Department of Endocrinology, Austin Health, Heidelberg, Victoria, Australia (Cheung).

Author Contributions: Drs Nolan and Cheung had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: All authors.

Acquisition, analysis, or interpretation of data: Nolan, Cheung.

Drafting of the manuscript: Nolan.

Critical review of the manuscript for important intellectual content: All authors.

Statistical analysis: Nolan.

Obtained funding: Cheung.

Administrative, technical, or material support: Locke.

Supervision: Cheung.

Conflict of Interest Disclosures: Drs Nolan and Cheung reported receiving product from Besins Healthcare for separate investigator-initiated clinical studies using estradiol and progesterone. No other disclosures were reported.

Funding/Support: Dr Nolan is supported by a National Health and Medical Research Council Postgraduate Scholarship (No. 2003939) and Royal Australasian College of Physicians-Endocrine Society of Australia Research Establishment Fellowship. Dr Cheung is supported by an Australian Government National Health and Medical Research Council Investigator Grant (No. 2008956). This project was supported by the Endocrine Society of Australia Ferring Innovation and Clinical Excellence Award.

Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Data Sharing Statement: See [Supplement 3](#).

Additional Information: Study data were collected and managed using REDCap electronic data capture tools hosted at The University of Melbourne.

REFERENCES

1. Nolan BJ, Zwickl S, Locke P, Zajac JD, Cheung AS. Early access to testosterone therapy in transgender and gender-diverse adults seeking masculinization: a randomized clinical trial. *JAMA Netw Open*. 2023;6(9):e2331919. doi:10.1001/jamanetworkopen.2023.31919
2. van Leerdam TR, Zajac JD, Cheung AS. The effect of gender-affirming hormones on gender dysphoria, quality of life, and psychological functioning in transgender individuals: a systematic review. *Transgend Health*. 2023;8(1):6-21. doi:10.1089/trgh.2020.0094
3. Doyle DM, Lewis TOG, Barreto M. A systematic review of psychosocial functioning changes after gender-affirming hormone therapy among transgender people. *Nat Hum Behav*. 2023;7(8):1320-1331. doi:10.1038/s41562-023-01605-w
4. Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). *Qual Life Res*. 2011;20(10):1727-1736. doi:10.1007/s11136-011-9903-x
5. Devlin NJ, Shah KK, Feng Y, Mulhern B, van Hout B. Valuing health-related quality of life: An EQ-5D-5L value set for England. *Health Econ*. 2018;27(1):7-22. doi:10.1002/hec.3564
6. Vickers AJ, Altman DG. Statistics notes: Analysing controlled trials with baseline and follow up measurements. *BMJ*. 2001;323(7321):1123-1124. doi:10.1136/bmj.323.7321.1123

SUPPLEMENT 1.

Trial Protocol

SUPPLEMENT 2.

eFigure. Study Subjects and Flow of Participants

SUPPLEMENT 3.

Data Sharing Statement